238 related articles for article (PubMed ID: 20151975)
1. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases.
Cooper N; Arnold DM
Br J Haematol; 2010 Apr; 149(1):3-13. PubMed ID: 20151975
[TBL] [Abstract][Full Text] [Related]
2. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
[TBL] [Abstract][Full Text] [Related]
3. Rituximab-associated infections.
Gea-Banacloche JC
Semin Hematol; 2010 Apr; 47(2):187-98. PubMed ID: 20350666
[TBL] [Abstract][Full Text] [Related]
4. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells.
Liossis SN; Sfikakis PP
Clin Immunol; 2008 Jun; 127(3):280-5. PubMed ID: 18337174
[TBL] [Abstract][Full Text] [Related]
5. Does rituximab aggravate pre-existing hypogammaglobulinaemia?
Diwakar L; Gorrie S; Richter A; Chapman O; Dhillon P; Al-Ghanmi F; Noorani S; Krishna MT; Huissoon A
J Clin Pathol; 2010 Mar; 63(3):275-7. PubMed ID: 20203231
[TBL] [Abstract][Full Text] [Related]
6. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
[TBL] [Abstract][Full Text] [Related]
7. [B cells as key contributors in determining the level of immune responses -B-cell-targeted therapy in patients with autoimmune diseases].
Kondo S; Akashi T; Katsuta H; Iwakiri R; Anzai K; Nagafuchi S; Niho Y; Harada M
Fukuoka Igaku Zasshi; 2005 Apr; 96(4):86-92. PubMed ID: 15991605
[TBL] [Abstract][Full Text] [Related]
8. B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders.
Stübgen JP
J Neuroimmunol; 2008 Nov; 204(1-2):1-12. PubMed ID: 18783837
[TBL] [Abstract][Full Text] [Related]
9. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.
Albert D; Dunham J; Khan S; Stansberry J; Kolasinski S; Tsai D; Pullman-Mooar S; Barnack F; Striebich C; Looney RJ; Prak ET; Kimberly R; Zhang Y; Eisenberg R
Ann Rheum Dis; 2008 Dec; 67(12):1724-31. PubMed ID: 18250115
[TBL] [Abstract][Full Text] [Related]
10. B cell targeted therapy in autoimmunity.
Blank M; Shoenfeld Y
J Autoimmun; 2007; 28(2-3):62-8. PubMed ID: 17391915
[TBL] [Abstract][Full Text] [Related]
11. Rituximab: a B-cell depletion therapy for dermatologic disease.
Prajapati V; Mydlarski PR
Skin Therapy Lett; 2007; 12(6):6-9. PubMed ID: 17762903
[TBL] [Abstract][Full Text] [Related]
12. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases.
El-Hallak M; Binstadt BA; Leichtner AM; Bennett CM; Neufeld EJ; Fuhlbrigge RC; Zurakowski D; Sundel RP
J Pediatr; 2007 Apr; 150(4):376-82. PubMed ID: 17382113
[TBL] [Abstract][Full Text] [Related]
13. A review of the current use of rituximab in autoimmune diseases.
Gürcan HM; Keskin DB; Stern JN; Nitzberg MA; Shekhani H; Ahmed AR
Int Immunopharmacol; 2009 Jan; 9(1):10-25. PubMed ID: 19000786
[TBL] [Abstract][Full Text] [Related]
14. B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis.
Looney RJ
Rheumatology (Oxford); 2005 May; 44 Suppl 2():ii13-ii17. PubMed ID: 15851522
[TBL] [Abstract][Full Text] [Related]
15. B cells move to centre stage: novel opportunities for autoimmune disease treatment.
Browning JL
Nat Rev Drug Discov; 2006 Jul; 5(7):564-76. PubMed ID: 16816838
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in refractory autoimmune bullous diseases.
Schmidt E; Hunzelmann N; Zillikens D; Bröcker EB; Goebeler M
Clin Exp Dermatol; 2006 Jul; 31(4):503-8. PubMed ID: 16716150
[TBL] [Abstract][Full Text] [Related]
17. Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis.
Taylor RP; Lindorfer MA
Nat Clin Pract Rheumatol; 2007 Feb; 3(2):86-95. PubMed ID: 17299446
[TBL] [Abstract][Full Text] [Related]
18. Rituximab in chronic lymphocytic leukemia.
Jaglowski SM; Byrd JC
Semin Hematol; 2010 Apr; 47(2):156-69. PubMed ID: 20350663
[TBL] [Abstract][Full Text] [Related]
19. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases.
Kazkaz H; Isenberg D
Curr Opin Pharmacol; 2004 Aug; 4(4):398-402. PubMed ID: 15251135
[TBL] [Abstract][Full Text] [Related]
20. B-cell compartment as the selective target for the treatment of immune thrombocytopenias.
Zaja F; Vianelli N; Sperotto A; De Vita S; Iacona I; Zaccaria A; Masolini P; Tomadini V; Tani M; Molinari AL; Baccarani M; Fanin R
Haematologica; 2003 May; 88(5):538-46. PubMed ID: 12745273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
